1. Medtech Insight
  2. >>Device Area

EuroPCR 2018: Abbott's Tendyne Mitral Valve Shows Early Promise

 
• By Tina Tan

Early data from Abbott's CE mark study of its mitral valve replacement technology Tendyne shows the device's potential in reducing mitral regurgitation in severe mitral regurgitation patients.

MT1805_Eiffel Tower_710380270 _1200
EuroPCR 2018 is held in Paris, France between May 22-25

Tendyne, the mitral valve replacement technology that Abbott Laboratories Inc. acquired three years ago, has potential to successfully treat patients with severe mitral regurgitation, according to early follow-up data presented May 23 at EuroPCR in Paris.

The results from a single-arm, multicentre global study to support the CE mark of Tendyne were presented at EuroPCR by principal investigator David Muller of St Vincent's Hospital, Sydney, Australia....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.